https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
essary to inform evidence-based practice.Many countries with the highest burdens of cervical cancer have not yet offered HPV vaccines to the majority of their age-eligible girls, who as adults also have limited or no access to effective cervical cancer screening or treatment. There are now two complementary developments that could make HPV vaccines more accessible and affordable 1) the current and projected increases in HPV vaccine supply and 2) the permissive recommendation for single-dose HPV vaccination schedules. This c